Domenico Milardi1,2
Giuseppe Grande1,2*
Federica Vincenzoni3,4
Francesco Pierconti5Alfredo Pontecorvi1,2- 1International Scientific Institute “Paul VI”, Rome, Italy
- 2Division of Endocrinology, Fondazione Policlinico'A. Gemelli' IRCCS, Rome, Italy
- 3School of Medicine, Biochemistry and Clinical Biochemistry Institute, Catholic University of Rome, Rome, Italy
- 4Department of Laboratory Diagnostic and Infectious Diseases, Fondazione Policlinico'A. Gemelli' IRCCS, Rome, Italy
- 5Division of Anatomic Pathology and Histology, School of Medicine, Catholic University of Rome, Rome, Italy
A large number of biomarkers have been proposed for the diagnosis of testicular cancer, representing putative molecular targets for anticancer treatments. However, no conclusive data have been provided. Proteomics represents a research field recently developed. It evaluates the large-scale analysis of the full protein components of a single cell, of a specific tissue, or of biological fluids. In the last decades, proteomics has been applied in clinical fields, thanks to modern technology and new bioinformatic tools, to identify novel molecular markers of diseases. The aim of this review is to argue the findings of recent studies in the discoveries of putative prognostic and diagnostic markers of testis cancer by proteomic techniques. We present here a panel of proteins identified by proteomics which might be used after validation for early detection and the prognostic evaluation of testicular tumors. In addition, the molecular mechanisms revealed by these proteomic studies might also guide the development of novel treatments in future.
Introduction
Testicular germ cell tumors (TGCT) is the most frequent cancer occurring in young men. TGCTs are classified into two subgroups: non-seminoma and seminomas germ cell tumors. Seminomas rate for 50% of testicular cancer and non-seminoma germ cell tumors rate for 40% of testicular cancer. The remaining 10% of testicular cancer is associated with tumors and they usually include both seminoma and non-seminoma components (1). The difference in the diagnosis between seminoma and non-seminoma is fundamental for the objective of treatment and of prognosis.
TGCTs originate from transformed gonocytes or undifferentiated spermatogonia, but the pathogenesis of TGCT remains unexplored (2). To date, accessible markers for the diagnosis and follow-up aftercare include a-fetoprotein (AFP), ßHCG and LDH. However, AFP and ßhCG have high specificity (90%) but often relatively low sensitivity. For this reason tumor markers alone are not able to detect many recurrences, indeed in about 40% of men with disease recurrence the levels of these markers are usually “normal.” The LDH appears to have poor diagnostic performance (3). Therefore, the discovery of novel clinical biomarkers would clearly help the early detection and the monitor of the disease.
The diagnosis of “cancer” can be challenging. In addition to histopathological interpretation and immunohistochemical stains for confirming the precise cell of origin (4), more recently global gene expression profiling has been applied in order to facilitate the treatment decisions and prognosis. One key application for patients with the primary disease is precise prognosis, which helps to divide patients into different risk groups and select both treatment and monitoring strategies. Usually, the prognosis is based on clinical parameters such as age and tumor stage. Recently, considerable attempts have been made to incorporate molecular information in the staging process for accurate prognosis. Different tumors are classified in accordance to similar gene expression patterns. They represent a “molecular signature,” composed by several tens or hundreds of genes, in particular with regard to cell morphology or tissue characteristics. Global gene expression is most easily measured using cellular RNA; on the other hand, protein expression profiling provides a more dynamic view, offering additional informations on protein-protein interactions, post-trasductional modifications and finally on protein abundance (5).
Testicular cancer has been mainly studied at a genetic level. However, proteomics represents a promising technology that could allow novel insight into the disease at the molecular level to increase the understanding of their function. In the present molecular era proteomic is evaluated as a crucial point in personalized medicine to identificate specific target proteins for the pathophysiological state. Moreover, modern bioinformatic analysis offers information about the involvement of the proteins in the biological pathways of the tumor (6). Proteomics analysis of testicular tumor compared to normal testicular tissue may create a platform for enhanced understanding of differentially expressed proteins which might represent potential biomarkers for cancer. Protein expression profiling is a powerful tool in clinical practice, particularly in identifying cancer biomarkers to help the diagnosis and to choose a personalized treatment and monitoring of patients.
In the field of testicular tumors, particularly, the studies are few and outdated. Currently the main problem in the identification of protein markers is the small number of proteins which have been associated to TGCT.
Proteomic Technologies Applied in TGCT: Features and Performances
Technological advances in proteomics have improved sensitivity and multiplexing ability of the method, as well as the possibility of identifying protein interactions. These advances can be of help to understand the molecular mechanisms involved in TGCT. The use of proteomics technologies offers an appealing approach to the identification and development of new tools to be used in clinical practice, identified by the simultaneous comparison of hundreds or thousands of proteins. The development and use of performant sample preparation techniques together with the increasing availability of proteomics technologies and recent technical advances in mass spectrometry (MS) enable identification and quantification of proteins involved in the diseases, although they are expressed at low abundance (7).
Up to now the most common proteomics technologies applied in the studies about TGCT include “gel-based” proteomics such as 2D-PAGE and 2D-electrophoresis associated with mass spectrometry (MS). SELDI-TOF and High-performance liquid chromatography (HPLC) associated with tandem mass spectrometry (MS/MS) moreover have been used in two studies. One additional proteomic study was performed in serum by SELDI-TOF.
Separation Techniques
2D Gel Electrophoresis
2D gel electrophoresis detaches proteins consistent with their isoelectric point. A second, independent separation step is then performed, dependent on mass (molecular weight), using sodium dodecyl sulfate polyacrylamide gel electrophoresis. This 2D-PAGE method can be performed to develop samples at high resolution and on a large scale. It might represent a primary screening method to form hypotheses and to guide further researches. 2D gel electrophoresis is the most frequently performed technique for proteomic analysis, although some limitations which are related to protein solubility (i.e., membrane proteins not easily solubilized), poor protein separation in the initial pH gradient (too basic or too acidic proteins) and low and high molecular weight (8, 9).
To better identify the separated proteins, proteases may be used to digest bands or spots obtained 2D-electrophoresis. The smaller fragments are then ionized and analyzed by mass spectrometry (MS).
High-Performance Liquid Chromatography (HPLC)
HPLC is used with the aim to obtain a complete protein recovery, including small basic and hydrophobic types (9). In fact, protein separation is based on some specific protein properties (hydrophobicity, surface charges, specific amino acid sequences) (10). Connecting HPLC with a mass spectrometer it is possible to obtain the rapid separation and the comprehensive identification of components of a complex protein mixture, with the aim to deeply analyze a proteome.
Proteomic Analysis
Mass Spectrometry (MS)
MS-based techniques can be used to study complex protein mixtures previously fractionated by electrophoresis or HPLC. This technology provides precise mass values by the measurement of the mass-to-charge ratio (m/z) of the ions generated from the peptides and the proteins. In recent years a significant technical improvement of mass spectrometers has been observed. Modern mass spectrometers, such as time of flight (TOF), Fourier transform ion cyclotron resonance (FT- ICR) and Orbitrap detectors provide extremely accurate masses of analytes (11). Makarov invented the Orbitrap in 1999, as a mass analyzer that couples high resolution with high mass-accuracy, a significant m/z range and a high dynamic range (12, 13). The high mass-accuracy of the Orbitrap significantly contributes to the amount of acquired data and the number of analytic approaches that can be connected to MS (14).
SELDI TOF-MS
Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI TOF-MS) has been used widely in biomarker discovery because its sensitivity. It requires moreover only a small amount of protein for analysis. This method decreases the sample complexity by studying proteins with a specific chemical property that allows them to be adsorbed in a known surface (e.g., a charged, hydrophobic, or functionalized affinity surface). The non-bound protein population is removed by extensive washing. The adsorbed sample is ionized and analyzed (15).
Proteomics of TGCT Tissue
Table 1 summarizes the proposed putative markers which have been identified in TGCT tissue.
Table 1. Proteins identified through proteomics as putative markers in TGTC tissue.
For the first time in 2006 Zimmermann et al applied proteomic analysis to neoplastic germ cell tissue (16). This strategy has been applied to identify differences in the proteomes obtained by non-neoplastic and neoplastic tissues. Protein extracts have been analyzed by 2DPAGE combined with mass spectrometry. The comparative study permitted the identification and detection of quantitative differences of expressed proteins between seminoma and non-seminoma tissue.
Glutathione S-transferase (GSTs) M3 protein has been downregulated in seminoma tissues. GSTs detoxification enzymes partecipate in the pathogenesis of cancers. GSTM3 is a critical GSTs variant and previous evidences showed that GSTM3 polymorphism is associated with an increased risk to develope a cancer (20, 21). A lot of studies previously investigated the association of GSTM3 gene polymorphism with the risk to develop a lung cancer. Furthermore, a reduction in GST protein level was earlier reported in human TGCT (22), but the M3 isoform has not been previously identified in TGCT. Only proteomics permitted the identification of this specific isoform, as possibly associated with testis cancer. The M3 homodimer is a specific isoform specifically identified in the brain and in the testis (23). The GSTM3 gene is polymorphic and GSTM3 polymorphisms control the enzyme activity by the modulation of substrate binding (24). Distinct polymorphisms of GST-M3 enzyme are associated with a higher risk for TGCT formation (16). In particular, the study published in 2009, performed on a large population of patients who survived TGCT, reported that GSTP1 genotype influences the risk of developing a TGCT (25). M3 and P1 polymorphisms of GSTM3 represent promising markers for predicting the risk of TGTC formation.
In 2009 Leman et al. used a proteomics analysis to discover a pattern of proteins related with nuclear changes in seminoma cells (17). The changes in the form and in the size of the nucleus are trademarks of the cancer cell. Proteomics approach focused to mark a specific pattern of proteins related with the specific alterations in the nuclear structure of seminoma cells. Using high-resolution two dimensional gels, four nuclear matrix proteins have been identified in seminomas, but not in the normal tubules and three of these four proteins are part of gamma-tubulin complex component 6 (GCP6).
The γ-tubulin complex is a large multiprotein complex which plays an essential role in microtubule nucleation at the centrosome. C-tubulin ring complex (c-TuRC) is a key component of the centrosome which nucleates microtubules. GCP6 is localized in the pericentriolar material, a protein matrix composed by protein complexes involved in centrosome-associated functions (i.e., microtubule nucleation). Moreover, GCP6 is needed for centriole duplication and Polo-like kinase4 (Plk4)-induced centriole over-duplication. GCP6 interacts in fact with Plk4 and it is phosphorylated by the same Plk4. Therefore, controlling centriole numbers GCP6 preserves cells to have the correct number of centrosomes and cilia. Excessive number of centrioles lead to tumorigenesis in flies (26) and has been associated with chromosomal instability in humans (27).
Another specific protein for seminomas is Cyclin-dependent kinase 10 (CDK10). CDK10 is a Cdc2-related kinase and is a key element in the advance from the G2 to M phase transition of the cell cycle. Two isoforms of CDK10 have been documented: HCDK10-1 and HCDK10-2 (17). CDK10 is highly represented in colorectal cancer where it takes part in the suppression of apoptosis and in the stimulation of tumor growth in vitro and in vivo. The modulation of CDK10 expression in colorectal cancer indicates that CDK10 is involved in cell growth and it is associated with a reduction in chemosensitivity. Finally it inhibits apoptosis through the upregulation of the expression of Bcl-2 (28). Both the CDK10 isoforms are expressed in the nuclear matrix of the seminomas, supporting the role of CDK10 in the cell cycle regulation that may induce testicular cancer.
In normal testis moreover seven specific nuclear matrix proteins have been detected, which are absent in seminoma tissue. Some of these proteins are testis specific: Y177 encoded-like protein 4, cytokeratins, glutamine synthetase, and StAR-related lipid transfer protein 7 (StarD7).
StarD7 has been reported for the first time as related with nuclear matrix and it is part of the family of StAR1-related lipid transfer (START) proteins. These proteins are involved in lipid transport, metabolism and signaling (17). Overexpressed StARD7 gene has been specifically linked with colorectal cancer. StarD7 protein upregulation has been documented in differentiating cytotrophoblast suggesting that StarD7 might have a function in throphoblast differentiation through phospholipids uptake and transport (29). The loss of StarD7 protein in JEG-3 cells alters ABCG2 multidrug transporter level, cell migration, cell proliferation, and differentiation marker expression. StarD7, expressed in normal testis but not in seminoma tissue, might have a role in maintaining the differentiated form of the normal cells. The loss of StarD7 might induce cancer development.
The testicular microenvironment is a unique environment. Spermatogenesis and tumorigenesis at testicular level in humans are two biological processes which have got numerous similarities between them. It is very important to know the common mechanisms between the two biological processes. In 2013 Liu et al. performed an extensive study for tumor marker identification by proteomic of testicular tissues. Using 2D-high performance liquid chromatography (HPLC)–MS/MS (LTQ Orbitrap Velos hybrid mass spectrometer) the Authors identified 7,346 proteins in testis tissue with normal spermatogenesis (18).
The protein data were confirmed by immunohistochemistry and by comparison with previously published data from the Human Testis Proteome Database. These date have been confirmed by using of a GWAS study, using associated SNPs in case of differential expression of these proteins. Among these testicular proteins, six novel cancer/testis gene transmembrane protease have been characterized: serine 12 (TMPRSS12), tubulin polymerisation promoting protein family member 2 (TPPP2), protease serine 55 (PRSS55), double-sex and mab-3 related transcription factor 1 (DMRT1), piwi-like RNA-mediated gene silencing 1 (PIWIL1), and hemogen (HEMGN). The last four proteins have been proposed to exert a central role in spermatogenesis and cancer development, although they still haven't known specific functions in testis (18).
The Mab-3 doublesex- and Related Transcription Factor 1 (DMTR1) has been associated to prostate cancer. It is a controller of mitotic proliferation in germ cells, thanks to a specific zinc finger structural motif which is associated with cell cancer proliferation. A recent study confirmed these results in the human testis; nuclear expression of DMRT1 was reported in spermatogonia, but not in primary spermatocytes that have entered meiosis 1 or in more mature germ cells. DMRT1 expression was confirmed in the germ cells of testicular mixed germ cell–sex cord stromal tumor (MGC-SCST) and spermatocytic tumor but not in those of seminoma. For this reason the germ cells of MGC-SCST are related to spermatogonia, which espress DMRT1. The strong expression of DMRT1, together with the absence of TCLF5 in the germ cells of both MGC-SCST and spermatocytic tumor, suggests a premeiotic origin for both tumors (30).
The second protein is Piwi-Like RNA Mediated Gene silencing 1 (PIWIL1) which, together with the allelic variant rs10773777, was also detected in prostate cancer cases. PIWIL1 was also detected by proteomic approach as a specific protein of TGCT. This protein might play a pivotal function in RNA silencing during the modulation of tranlational activity. Previous studies reported that PIWIL1 plays an important role in cancer development, improving DNA methylation. Several cancer-germline genes have been defined to stimulate PIWIL1 as a part of oncogenic pathways involved in cell proliferation (31). More recently PIWIL1 expression was demonstrated in spermatocytes and spermatids. Up to 70% of TGCT samples express PIWIL1, which is not normally expressed in premeiotic germ cells. These evidences support that in many germ tumors is present an aberrant expression of PIWIL1. The enhanced expressions of piwil2 was found in seminomas and has not been reported in testicular non-seminomas tumors (31).
The third protein is Transmembrane (C-Terminal) Protease, Serine 12 (TMPRSS12). It was previously related with colorectal cancer for the variant rs11169552 (32). This protein has been demonstrated to be expressed in spermatids and spermatocytes (33). The Tubulin Polymerization-Promoting Protein Family Member 2 (TPPP2) and its variant rs1952524 was linked to liver cancer (34). Another protein is the Protease Serine 55 (PRSS55) along with the variant rs4404875, which has been mainly identified in Leydig and Sertoli cells and it is is associated with prostate and ovarian cancer (35). Finally Hemogein (HEMGN), which regulates proliferation and differentiation in hematopoietic cells, has been associated with thyroid cancer (36). Among the 300 proteins expressed in human testis, only 22.7% are TGCT-related proteins, of which only 65 proteins have been evaluated, indicating that other candidate proteins exist, although not still studied, The functional analysis of only 65 out 300 proteins might depend to still low sensitive methods in the field of proteomics. The six proteins previously cited might represent moreover important targets for personalized therapy in this kind of neoplasy (18).
In a very recent study, Castillo et al. identified 174 phosphorylated kinases in human testis by metal oxide affinity chromatography using TiO2 combined with LC-MS/MS. Protein phosphorylation is involved in the modulation of cell cycle, cell growth, cell differentiation and cell death. Two kinases have been studied in the testis phosphoproteome as candidates for further studies by immunodetection procedures. Immunodetection has been specifically used to study the potential function of cyclin dependent kinase 12 (CDK12) and p21-activated kinase 4 (PAK4) in testicular tissue. The in silico protein-protein interactions have been studied, and a functional analysis in a human embryonal carcinoma cell line has been performed. PAK4 is localized in human spermatogonia. Its function in preventing the activation of caspase is well-known. In embryonal carcinoma it has been observed that PAK4 protects cells from apoptosis. PAK4 inhibitors might represent an interesting pharmacological target for novel drugs modulating behavior of testicular cancer (19).
Proteomics of TCGC in Serum
Protein markers that distinguish cancer patients by healthy controls can be moreover searched in serum.
A single serum proteomic study regarding testis cancer was carried out. In 2010, Strenziok et al utilizing Surface-enhanced laser desorption ionization time-of-Xight mass spectrometry (SELDI-TOF MS) identified the protein profiles of TGCT patients that are different in a highly significant degree from normal subjects (37). CM10 ProteinChip® array identified 138 peaks in a mass range of 3,800–10,000 Da that might repredent a “molecular fingerprint” to differentiate tumor serum sample from non-tumor serum samples. The spectra of proteins have been investigated by the proteomic platform “proteomic.net.” Five peaks have been verified by CM10 ProteinChip® (6.48, 6.84, 8.15, 8.17, 8.92 kDa). There was no single peak that could discriminate the group of seminoma vs. control subjects, so a cluster classifications has been performed.
For statistical analysis, an artificial intelligence learning algorithm used three different bioinformatics methods to develop the training set for the decision trees, support vector machines, and neural networks and to differentiate between the two groups. Decision tree analyses developed the most powerful classifier with 89.4% specificity and 91.5% sensitivity (CM10 ProteinChip®, 95% confidence interval of 82.6–95.5%).
In this study the authors after the first step in investigation separating cancer from healthy controls with the definition of protein profiles of TGCT patients that differ in a highly significant degree from normal controls; the protein identification of peak masses was not necessary to differentiate cancer patients from healthy subjects.
Validation of these results may permit proteomic profiling to become a useful tool especially for aftercare follow up.
Conclusions
In the past 20 years molecular biomarker identification achieved importance in the field of personalized medicine, aimed to identify a cancer in the early stages and to develop novel therapeutical approaches. According to these premises, the discovery of novel specific markers would help the management of patients with testicular cancer.
Proteomics has proven to represent a promising platform for identifying biomarkers linked to testicular cancer.
The conventional tumor markers AFP, hCG, and LDH have demonstrated value in the clinical management of testicular malignant TGCT. However, their limitations in sensitivity and specificity prevent more universal application, especially in patients with seminoma. Tissue and serum biomarkers show exciting promises in the identification of markers for the diagnostics of TGCT. Furthermore, no proteomic studies have been permorfed aimed to detect markers of TGCT in semen, although it represents a promising source of putative biomarkers in different clinical situations (38–40).
Proteomic identification of TGCT-related proteins will allow to validate candidate markers for early detection and the prognostic evaluation of testicular tumors. In addition, the molecular mechanisms revealed by these proteomic studies might also guide the development of novel treatments in future.
Author Contributions
DM and GG: conceptualization and writing—original draft preparation. DM and FP: literature analysis. FV and AP: writing—review and editing. AP: supervision.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The authors thank Esther Mahoney (Cardiff, UK) for her kind and careful English editing.
References
1. Vasdev N, Moon A, Thorpe AC. Classification, epidemiology and therapies for testicular germ cell tumours. Int J Dev Biol. (2013) 57:133–9. doi: 10.1387/ijdb.130031nv
2. Rajpert-De Meyts E. Developmental model for the pathogenesis of testicular carcinoma in situ: genetic and environmental aspects. Hum Reprod Update. (2006) 12:303–23. doi: 10.1093/humupd/dmk006
3. Nicholson BD, Jones NR, Protheroe A, Joseph J, Roberts NW, Van den Bruel A, et al. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: a diagnostic test accuracy systematic review. Cancer Epidemiol. (2019) 59:15–21. doi: 10.1016/j.canep.2019.01.001
4. Pierconti F, Milardi D, Martini M, Grande G, Cenci T, Gulino G, et al. Pituitary-tumour-transforming-gene 1 expression in testicular cancer. Andrologia. (2015) 47:427–32 doi: 10.1111/and.12283
5. Maes E, Mertens I, Valkenborg D, Pauwels P, Rolfo C, Baggerman G. Proteomics in cancer research: are we ready for clinical practice? Crit Rev Oncol Hematol. (2015) 96:437–48. doi: 10.1016/j.critrevonc.2015.07.006
6. Han X, Aslanian A, Yates JR. Mass spectrometry for proteomics. Curr Opin Chem Biol. (2008) 12:483–90. doi: 10.1016/j.cbpa.2008.07.024
7. Fey SJ, Larsen PM. 2D or not 2D. two-dimensional gel electrophoresis. Curr Opin Chem Biol. (2001) 5:26–33. doi: 10.1016/S1367-5931(00)00167-8
8. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics. (2002) 2:3–10. doi: 10.1002/1615-9861(200201)2:1<3::AID-PROT3>3.0.CO;2-R
9. Veveris-Lowe T, Kruger S, Walsh T, Gardiner R, Clements J. Seminal fluid characterization for male fertility and prostate cancer: kallikrein-related serine proteases and whole proteome approaches. Semin Thromb Hemost. (2007) 33:87–99. doi: 10.1055/s-2006-958467
10. Mitulovic G, Mechtler K. HPLC techniques for proteomics analysis–a short overview of latest developments. Briefings Funct Genomics Proteomics. (2006) 5:249–60. doi: 10.1093/bfgp/ell034
11. Makarov A, Scigelova M. Coupling liquid chromatography to orbitrap mass spectrometry. J Chromatogr A. (2010) 1217:3938–45. doi: 10.1016/j.chroma.2010.02.022
12. Hu Q, Noll RJ, Li H, Makarov A, Hardman M, Graham Cooks R. The orbitrap: a new mass spectrometer. J Mass Spectrom. (2005) 40:430–43. doi: 10.1002/jms.856
13. Makarov A, Denisov E, Lange O, Horning S. Dynamic range of mass accuracy in LTQ orbitrap hybrid mass spectrometer. J Am Soc Mass Spectrom. (2006) 17:977–82. doi: 10.1016/j.jasms.2006.03.006
14. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu Rev Biomed Eng. (2009) 11:49–79. doi: 10.1146/annurev-bioeng-061008-124934
15. Kiehntopf M, Siegmund R, Deufel T. Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potential and limitations. Clin Chem Lab Med. (2007) 45:1435–49. doi: 10.1515/CCLM.2007.351
16. Zimmermann U, Junker H, Krämer F, Balabanov S, Kleist B, Kammer W, Nordheim A, et al. Comparative proteomic analysis of neoplastic and non-neoplastic germ cell tissue. Biol Chem. (2006) 387:437–40. doi: 10.1515/BC.2006.058
17. Leman ES, Magheli A, Yong KMA, Netto G, Hinz S, Getzenberg RH. Identification of nuclear structural protein alterations associated with seminomas. J Cell Biochem. (2009) 108:1274–9. doi: 10.1002/jcb.22357
18. Liu M, Hu Z, Qi L, Wang J, Zhou T, Guo Y, Zeng Y, et al. Scanning of novel cancer/testis proteins by human testis proteomic analysis. Proteomics. (2013) 13:1200–10. doi: 10.1002/pmic.201200489
19. Castillo J, Knol JC, Korver CM, Piersma SR, Pham TV, Goeij de Haas RR, et al. Human testis phosphoproteome reveals kinases as potential targets in spermatogenesis and testicular cancer. Mol Cell Proteomics. (2019) 8(Suppl 1):S132–44. doi: 10.1074/mcp.RA118.001278
20. Singh H, Sachan R, Devi S, Pandey SN, Mittal B. Association of GSTM1, GSTT1, and GSTM3 gene polymorphisms and susceptibility to cervical cancer in a North Indian population. Am J Obstet Gynecol. (2008) 198:303.e1–303.e6. doi: 10.1016/j.ajog.2007.09.046
21. Kesarwani P, Singh R, Mittal RD. Association of GSTM3 intron 6 variant with cigarette smoking, tobacco chewing and alcohol as modifier factors for prostate cancer risk. Arch Toxicol. (2009) 83:351–6. doi: 10.1007/s00204-008-0343-5
22. Institoris E, Eid H, Bodrogi I, Bak M. Differential expression of glutathione S-transferases in germ cell tumors of human testes. Anticancer Res. (1998) 18:1727–31.
23. Campbell E, Takahashi Y, Abramovitz M, Peretz M, Listowsky I. A distinct human testis and brain mu-class glutathione S-transferase. molecular cloning and characterization of a form present even in individuals lacking hepatic type mu isoenzymes. J Biol Chem. (1990) 265:9188–93.
24. Tetlow N, Robinson A, Mantle T, Board P. Polymorphism of human mu class glutathione transferases. Pharmacogenetics. (2004) 14:359–68. doi: 10.1097/00008571-200406000-00005
25. Kraggerud SM, Oldenburg J, Alnaes GI, Berg M, Kristensen VN, Fossa SD, et al. Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology. Pharmacogenet Genomics. (2009) 19:751–9. doi: 10.1097/FPC.0b013e3283304253
26. Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A, et al. Centrosome amplification can initiate tumorigenesis in flies. Cell. (2008) 133:1032–42. doi: 10.1016/j.cell.2008.05.039
27. Ganem NJ, Godinho SA, Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. (2009) 460:278–82. doi: 10.1038/nature08136
28. Weiswald L-B, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, et al. Inactivation of the kinase domain of CDK10 prevents tumor growth in a preclinical model of colorectal cancer, and is accompanied by downregulation of Bcl-2. Mol Cancer Ther. (2017) 16:2292–303. doi: 10.1158/1535-7163.MCT-16-0666
29. Angeletti S, Rena V, Nores R, Fretes R, Panzetta-Dutari GM, Genti-Raimondi S. Expression and localization of StarD7 in trophoblast cells. Placenta. (2008) 29:396–404. doi: 10.1016/j.placenta.2008.02.011
30. Roth LM, Michal M, Michal M, Cheng L. Protein expression of the transcription factors DMRT1, TCLF5, and OCT4 in selected germ cell neoplasms of the testis. Hum Pathol. (2018) 82:68–75. doi: 10.1016/j.humpath.2018.07.019
31. Hempfling AL, Lim SL, Adelson DL, Evans J, O'Connor AE, Qu ZP, et al. Expression patterns of HENMT1 and PIWIL1 in human testis: implications for transposon expression. Reproduction. (2017) 154:363–74. doi: 10.1530/REP-16-0586
32. Lubbe SJ, Whiffin N, Chandler I, Broderick P, Houlston RS. Relationship between 16 susceptibility loci and colorectal cancer phenotype in 3146 patients. Carcinogenesis. (2012) 33:108–12. doi: 10.1093/carcin/bgr243
33. Takano N, Kimura A, Takahashi T. Two distinct localization patterns of testis-specific serine protease 1 (TESSP1) in the seminiferous tubules of the mouse testis. Zoolog Sci. (2009) 26:294–300. doi: 10.2108/zsj.26.294
34. Inokawa Y, Sonohara F, Kanda M, Hayashi M, Nishikawa Y, Sugimoto H, Kodera Y, et al. Correlation between poor prognosis and lower TPPP gene expression in hepatocellular carcinoma. Anticancer Res. (2016) 36:4639–46. doi: 10.21873/anticanres.11014
35. Neth P, Profanter B, Geissler C, Nägler DK, Nerlich A, Sommerhoff CP, et al. T-SP1: a novel serine protease-like protein predominantly expressed in testis. Biol Chem. (2008) 389:1495–504. doi: 10.1515/BC.2008.170
36. Li CY, Zhan YQ, Xu CW, Xu WX, Wang SY, Lv J, et al. EDAG regulates the proliferation and differentiation of hematopoietic cells and resists cell apoptosis through the activation of nuclear factor-κB. Cell Death Differ. (2004) 11:1299–308. doi: 10.1038/sj.cdd.4401490
37. Strenziok R, Hinz S, Wolf C, Conrad T, Krause H, Miller K, et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry: serum protein profiling in seminoma patients. World J Urol. (2010) 28:193–7. doi: 10.1007/s00345-009-0434-9
38. Milardi D, Grande G, Vincenzoni F, Castagnola M, Marana R. Proteomics of human seminal plasma: Identification of biomarker candidates for fertility and infertility and the evolution of technology. Mol Reprod Dev. (2013) 80:350–7. doi: 10.1002/mrd.22178
39. Grande G, Vincenzoni F, Mancini F, Baroni S, Luca G, Calafiore R, et al. Semen proteomics reveals the impact of Enterococcus faecalis on male fertility. Protein Pept Lett. (2018) 25:472–477. doi: 10.2174/0929866525666180412161818
Keywords: testis cancer, proteomics, biomarker, germ cell tumor, proteins
Citation: Milardi D, Grande G, Vincenzoni F, Pierconti F and Pontecorvi A (2019) Proteomics for the Identification of Biomarkers in Testicular Cancer–Review. Front. Endocrinol. 10:462. doi: 10.3389/fendo.2019.00462
Received: 28 February 2019; Accepted: 25 June 2019;
Published: 12 July 2019.
Edited by:
Veronica Vella, University of Catania, ItalyCopyright © 2019 Milardi, Grande, Vincenzoni, Pierconti and Pontecorvi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giuseppe Grande, Z3JhbmRlZ2l1cyYjeDAwMDQwO2dtYWlsLmNvbQ==